Scarica l'app Stockscreener
308.44
5.12%
15.03
Dopo l'orario di chiusura:
308.44
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MDGL Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$293.41
Aprire:
$294
Volume 24 ore:
688.42K
Relative Volume:
1.65
Capitalizzazione di mercato:
$6.73B
Reddito:
-
Utile/perdita netta:
$-518.67M
Rapporto P/E:
-16.03
EPS:
-19.24
Flusso di cassa netto:
$-438.32M
1 W Prestazione:
+1.29%
1M Prestazione:
-2.73%
6M Prestazione:
+15.18%
1 anno Prestazione:
+39.54%
Intervallo 1D:
$293.00
$312.52
Intervallo di 1 settimana:
$289.80
$315.09
Portata 52W:
$168.25
$368.29
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Nome
Madrigal Pharmaceuticals Inc
Settore
Industria
Telefono
404-380-9263
Indirizzo
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Confronta MDGL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
308.44 | 6.73B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-28 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-04-22 | Iniziato | BofA Securities | Underperform |
| 2024-03-15 | Aggiornamento | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Iniziato | Citigroup | Buy |
| 2024-02-26 | Downgrade | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Reiterato | Oppenheimer | Outperform |
| 2022-12-19 | Reiterato | H.C. Wainwright | Buy |
| 2022-12-19 | Reiterato | Piper Sandler | Overweight |
| 2022-12-19 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Ripresa | Goldman | Buy |
| 2020-11-24 | Ripresa | Evercore ISI | Outperform |
| 2020-11-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-05 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-01-30 | Iniziato | Canaccord Genuity | Buy |
| 2020-01-09 | Aggiornamento | UBS | Neutral → Buy |
| 2019-11-07 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-25 | Iniziato | Stifel | Hold |
| 2019-06-10 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-12-12 | Iniziato | B. Riley FBR | Neutral |
| 2018-11-19 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Iniziato | Citigroup | Buy |
| 2018-08-06 | Downgrade | Goldman | Buy → Neutral |
| 2018-06-28 | Iniziato | Raymond James | Mkt Perform |
Mostra tutto
Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie
Geode Capital Management LLC Boosts Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
9,031 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Acquired by Wellington Management Group LLP - MarketBeat
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Profit Outlook - Yahoo Finance
FDA Tracker: FDA Hands Out Atopic Dermatitis Approvals to Galderma, Organon - BioSpace
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Bought by Barclays PLC - MarketBeat
Madrigal Pharmaceuticals' SWOT analysis: rezdiffra launch key to stock's future - Investing.com
Y Intercept Hong Kong Ltd Takes Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
How To Trade (MDGL) - Stock Traders Daily
State Street Corp Increases Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Brokerages Set Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) PT at $347.33 - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $4.74 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals' SWOT analysis: rezdiffra's potential drives stock outlook - Investing.com India
Madrigal Pharmaceuticals' SWOT analysis: rezdiffra's potential drives stock outlook By Investing.com - Investing.com Australia
XTX Topco Ltd Invests $1.04 Million in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy? - MSN
BNP Paribas Financial Markets Has $2.07 Million Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals price target raised to $427 from $415 at JMP Securities - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock Position Lessened by The Manufacturers Life Insurance Company - MarketBeat
Madrigal Pharmaceuticals (LTS:0JXI) 9-Day RSI : 50.46 (As of Dec. 05, 2024) - GuruFocus.com
Madrigal Pharmaceuticals director Fred Craves sells shares worth $1.14 million - Investing.com
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is RTW Investments LP's Largest Position - MarketBeat
How to Take Advantage of moves in (MDGL) - Stock Traders Daily
Cinctive Capital Management LP Makes New Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
When Will Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Breakeven? - Simply Wall St
Charles Schwab Investment Management Inc. Boosts Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Fmr LLC Sells 5,458 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More - AOL
Martingale Asset Management L P Takes Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals (FRA:YDO1) 9-Day RSI : 56.49 (As of Dec. 01, 2024) - GuruFocus.com
Madrigal Pharmaceuticals (FRA:YDO1) Total Assets : €967.01 Mil (As of Sep. 2024) - GuruFocus.com
Erste Asset Management GmbH Makes New $49.75 Million Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Braidwell LP Takes $39.01 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
MDGL (Madrigal Pharmaceuticals) EBITDA : $-502.65 Mil (TTM As of Sep. 2024) - GuruFocus.com
Vestal Point Capital LP Buys New Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
1,852 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by Blueshift Asset Management LLC - MarketBeat
MDGL (Madrigal Pharmaceuticals) Shares Outstanding (EOP) : 21.81 Mil (As of Sep. 2024) - GuruFocus.com
Advantage Alpha Capital Partners LP Makes New $349,000 Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Intech Investment Management LLC Takes $1.28 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals (LTS:0JXI) Total Stockholders Equi - GuruFocus.com
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move - MSN
Eagle Asset Management Inc. Makes New Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
MDGL (Madrigal Pharmaceuticals) Total Inventories : $8.72 Mil (As of Sep. 2024) - GuruFocus.com
When (MDGL) Moves Investors should Listen - Stock Traders Daily
Non-alcoholic Steatohepatitis (NASH) Treatment Market 2032: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight - The Globe and Mail
Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra - MSN
Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024? - Insider Monkey
Madrigal Pharmaceuticals Engages with Investors at Key Conferences - MSN
Connor Clark & Lunn Investment Management Ltd. Decreases Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal shares hold as Cowen maintains price target on new data - Investing.com Canada
Madrigal Pharmaceuticals (FRA:YDO1) Peter Lynch Fair Value : N/A (As of Nov. 20, 2024) - GuruFocus.com
Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra (MDGL:NASDAQ) - Seeking Alpha
Madrigal Pharmaceuticals Inc Azioni (MDGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):